Rite Aid (RAD) surprised The Street today by reporting a profitable Q1 driven by strong pharmacy sales growth. Can drug stores such as Rite Aid and Walgreen’s (WAG) survive the threat from four-dollar-pill-pusher Wal-Mart (WMT).
Guy Adami tells the panel he still likes Rite Aid because the Brooks Eckerd deal will save them $150 million a year in perpetuity. And the deal gives Rite-Aid national exposure.
Jeff Macke also likes the stock.
Eric Bolling says it’s not bad for an “under-$10 stock.”
Eric Bolling says it’s not bad for an “under-$10 stock.”
______________________________________________________
Got something to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to fastmoney@cnbc.com.
Trader disclosure: On June 28 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Najarian Owns (IMMR); Bolling Owns (DIS), (T), (XOM), Sugar, Gold
